Quick Answer
TEVA PHARMACEUTICAL INDUSTRIES LTD reported Revenue From Contract With Customer Excluding Assessed Tax of $17.26 billion for the year ending 2025.
- TEVA PHARMACEUTICAL INDUSTRIES LTD showed an increase of +4.3% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from TEVA PHARMACEUTICAL INDUSTRIES LTD's annual report (Form 10-K), filed with the SEC on February 3, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), TEVA PHARMACEUTICAL INDUSTRIES LTD's Revenue From Contract With Customer Excluding Assessed Tax has declined by 21.2%.
- Historical annual values: Fiscal year 2025: $17.26 billion | Fiscal year 2024: $16.54 billion | Fiscal year 2023: $15.85 billion | Fiscal year 2022: $14.93 billion | Fiscal year 2021: $15.88 billion | Fiscal year 2020: $16.66 billion | Fiscal year 2019: $16.89 billion | Fiscal year 2018: $18.27 billion | Fiscal year 2017: $21.85 billion | Fiscal year 2016: $21.90 billion.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: